Nexell Therapeutics Inc.

The Irvine biotechnology company said it lost $7.1 million, or 37 cents a share, for the third quarter, compared with a net loss of $13 million, or 71 cents a share, a year ago. Revenue more than doubled to $4.5 million from $2.2 million.